Abstract
Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Current Pharmaceutical Design
Title:Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Volume: 19 Issue: 37
Author(s): Dana C. Baiu, Christopher S. Brazel, Yuping Bao and Mario Otto
Affiliation:
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Abstract: Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Export Options
About this article
Cite this article as:
C. Baiu Dana, S. Brazel Christopher, Bao Yuping and Otto Mario, Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/13816128113199990409
DOI https://dx.doi.org/10.2174/13816128113199990409 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Forceps: Still an Option?
Current Women`s Health Reviews Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Early Aged T-Cells in Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Endothelium in Aortic Aneurysm Disease: New Insights
Current Medicinal Chemistry How Do Microbubbles and Ultrasound Interact? Basic Physical, Dynamic and Engineering Principles
Current Pharmaceutical Design Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Regulation and Function of Rankl in Arterial Calcification
Current Pharmaceutical Design Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design